文献速递乳腺癌

与间期乳腺癌相关的遗传改变研究

Investigation of Genetic Alterations Associated With Interval Breast Cancer.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项基于瑞典人群的遗传关联研究纳入4121例乳腺癌患者(间期癌1229例,筛查检出癌2892例)及5631名年龄匹配对照,评估罕见胚系有害蛋白截断变异(PTV)能否在考虑乳腺X线密度的情况下区分间期癌与筛查检出癌。ATM、BRCA1、BRCA2、CHEK2和PALB2基因的PTV在间期癌中更常见(OR 1.48,95%CI 1.06-2.05),乳腺癌家族史与这些基因PTV协同增加间期癌诊断概率(OR 3.95,95%CI 1.97-7.92)。

要点

  • ATM、BRCA1、BRCA2、CHEK2和PALB2的PTV与间期癌风险相关(OR 1.48,95%CI 1.06-2.05)。
  • 乳腺癌家族史与上述基因PTV协同增加间期癌诊断概率(OR 3.95,95%CI 1.97-7.92)。
  • 间期癌中携带上述5基因PTV者10年乳腺癌特异性生存更差(HR 2.04,95%CI 1.06-3.92)。

核心结论

  • 研究结果可能有助于未来优化旨在降低死亡率的筛查项目以及乳腺癌患者的临床治疗。

研究设计与样本

  • 基于瑞典40至76岁参加乳腺X线筛查女性的基于人群的遗传关联研究。
  • 纳入2001年1月至2016年1月诊断为乳腺癌的全部女性及年龄匹配对照,乳腺癌患者随访生存至2021年。
  • 共4121例乳腺癌患者(间期癌1229例,筛查检出癌2892例),均为女性,平均(SD)年龄55.5(7.1)岁;年龄匹配对照5631名。
  • 暴露为经靶向测序分析的34个乳腺癌易感基因的胚系PTV。
  • 统计分析于2021年9月至2022年12月进行。

主要发现

  • ATM、BRCA1、BRCA2、CHEK2和PALB2基因的PTV在间期癌中较筛查检出癌更常见(OR 1.48,95%CI 1.06-2.05)。
  • 该关联主要受BRCA1/2和PALB2变异影响。
  • 乳腺癌家族史与上述任一基因PTV协同增加间期癌而非筛查检出癌的诊断概率(OR 3.95,95%CI 1.97-7.92)。
  • 10年乳腺癌特异性生存显示,间期癌中携带上述5基因任一PTV者较不携带者生存显著更差(HR 2.04,95%CI 1.06-3.92)。
  • 在既往筛查时乳腺X线密度低的间期癌亚组中,上述关联更为明显。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Breast cancers (BCs) diagnosed between 2 screening examinations are called interval cancers (ICs), and they have worse clinicopathological characteristics and poorer prognosis than screen-detected cancers (SDCs). However, the association of rare germline genetic variants with IC have not been studied. OBJECTIVE: To evaluate whether rare germline deleterious protein-truncating variants (PTVs) can be applied to discriminate between IC and SDC while considering mammographic density. DESIGN, SETTING, AND PARTICIPANTS: This population-based genetic association study was based on women aged 40 to 76 years who were attending mammographic screening in Sweden. All women with a diagnosis of BC between January 2001 and January 2016 were included, together with age-matched controls. Patients with BC were followed up for survival until 2021. Statistical analysis was performed from September 2021 to December 2022. EXPOSURE: Germline PTVs in 34 BC susceptibility genes as analyzed by targeted sequencing. MAIN OUTCOMES AND MEASURES: Odds ratios (ORs) were used to compare IC with SDC using logistic regression. Hazard ratios were used to investigate BC-specific survival using Cox regression. RESULTS: All 4121 patients with BC (IC, n = 1229; SDC, n = 2892) were female, with a mean (SD) age of 55.5 (7.1) years. There were 5631 age-matched controls. The PTVs of the ATM, BRCA1, BRCA2, CHEK2, and PALB2 genes were more common in patients with IC compared with SDC (OR, 1.48; 95% CI, 1.06-2.05). This association was primarily influenced by BRCA1/2 and PALB2 variants. A family history of BC together with PTVs of any of these genes synergistically increased the probability of receiving a diagnosis of IC rather than SDC (OR, 3.95; 95% CI, 1.97-7.92). Furthermore, 10-year BC-specific survival revealed that if a patient received a diagnosis of an IC, carriers of PTVs in any of these 5 genes had significantly worse survival compared with patients not carrying any of them (hazard ratio, 2.04; 95% CI, 1.06-3.92). All of these associations were further pronounced in a subset of patients with IC who had a low mammographic density at prior screening examination. CONCLUSIONS AND RELEVANCE: The results of this study may be helpful in future optimizations of screening programs that aim to lower mortality as well as the clinical treatment of patients with BC.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Rodriguez J, Grassmann F, Xiao Q, et al. Investigation of Genetic Alterations Associated With Interval Breast Cancer. JAMA Oncol. 2024. PMID: 38270937. doi:10.1001/jamaoncol.2023.6287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。